Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search:
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"CADTH Canadian Drug Expert Committee"
Showing
181
-
200
of
204
Search:
''
,
query time: 0.01s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
181
CADTH Canadian Drug Expert Committee recommendation: Isavuconazole (Cresemba -- Avir Pharma Inc.) : indication : for use in adults for the treatment of invasive aspergillosis, inva...
Published 2019
CADTH
Read Now
182
CADTH Canadian Drug Expert Committee recommendation: Semaglutide (Ozempic -- Novo Nordisk Canada Inc.) : indication : diabetes mellitus, type 2 to improve glycemic control
Published 2019
CADTH
Read Now
183
CADTH Canadian drug expert committee recommendation: Cysteamine ophthalmic solution (Cystadrops -- recordati rare diseases Canada Inc.) : indication : treatment of corneal cystine...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
184
CADTH Canadian Drug Expert Committee recommendation: Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) : indication : for the reduction of intraocular pressure (IOP) in...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
185
CADTH Canadian Drug Expert Committee recommendation: Baricitinib (Olumiant -- Eli Lilly Canada Inc.) : indication : for use in combination with methotrexate (MTX) for the treatment...
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
186
CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
187
CADTH Canadian Drug Expert Committee final recommendation: Selexipag (Uptravi -- Actelion Pharmaceuticals Canada Inc.) : Indication: pulmonary arterial hypertension
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
188
CADTH Canadian Drug Expert Committee recommendation: Brexpiprazole (Rexulti - Lundbeck Canada Inc and Otsuka Canada Pharmaceutical Inc.) : indication : treatment of schizophrenia i...
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
189
CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive mult...
Published 2018
CADTH
Read Now
190
CADTH Canadian Drug Expert Committee recommendation: Netupitant/palonosetron (Akynzeo -- Purdue Pharma) : indication : chemotherapy-induced nausea and vomiting
Published 2018
CADTH
Read Now
191
CADTH Canadian Drug Expert Committee recommendation: Tenofovir alafenamide (Vemlidy -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis B.
Published 2018
CADTH
Read Now
192
CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) : indication : Fabry disease
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
193
CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
194
CADTH Canadian Drug Expert Committee final recommendation: Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
195
CADTH Canadian Drug Expert Committee recommendation: Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
196
CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
197
CADTH Canadian Drug Expert Committee recommendation: Lumacaftor/Ivacaftor (Orkambi -- Vertex Pharmaceuticals (Canada) Incorporated) : indication : cystic fibrosis, F508del-cystic f...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
198
CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic--Ipsen Biopharmaceuticals Canada, Inc.) : indication : for the symptomatic treatment of...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
199
CADTH Canadian Drug Expert Committee final recommendation: Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
200
CADTH Canadian Drug Expert Committee final recommendation: Tiotropium/Olodaterol (Inspiolto Respimat - Boehringer Ingelheim Canada Ltd.) indication : chronic obstructive pulmonary...
Published 2015
Canadian Agency for Drugs and Technologies in Health
1
2
3
4
5
6
7
8
9
10
11
Back
Narrow Search
Remove Filters
Clear Filter
Author: CADTH Canadian Drug Expert Committee
Year of Publication
From:
To:
Classification
610 - Medicine & health
192
330 - Economics
111
140 - Specific philosophical schools
24
700 - The arts; fine & decorative arts
17
580 - Plants (Botany)
2
800 - Literature & rhetoric
2
Language
English
204
Collection
National Center for Biotechnology Information
204
Author
CADTH Canadian Drug Expert Committee
Canadian Agency for Drugs and Technologies in Health
152
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=10&filter%5B%5D=author_facet%3A%22CADTH+Canadian+Drug+Expert+Committee%22&type=AllFields
Send by Email
×
Loading...